Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
- Thiery-Vuillemin, A.
- de Bono, J.
- Hussain, M.
- Roubaud, G.
- Procopio, G.
- Shore, N.
- Fizazi, K.
- dos Anjos, G.
- Gravis, G.
- Joung, J.Y.
- Matsubara, N.
- Castellano, D.
- Degboe, A.
- Gresty, C.
- Kang, J.
- Allen, A.
- Poehlein, C.
- Saad, F.
ISSN: 1474-5488, 1470-2045
Année de publication: 2022
Volumen: 23
Número: 3
Pages: 393-405
Type: Article